These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31106152)

  • 1. The Role of New Technologies in Myeloproliferative Neoplasms.
    Palumbo GA; Stella S; Pennisi MS; Pirosa C; Fermo E; Fabris S; Cattaneo D; Iurlo A
    Front Oncol; 2019; 9():321. PubMed ID: 31106152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Consequences of Mutations in Myeloproliferative Neoplasms.
    Constantinescu SN; Vainchenker W; Levy G; Papadopoulos N
    Hemasphere; 2021 Jun; 5(6):e578. PubMed ID: 34095761
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Mroczkowska-Bękarciak A; Wróbel T
    Front Genet; 2023; 14():1241912. PubMed ID: 37745842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN.
    Zhang J; Shen K; Xiao M; Huang J; Wang J; Wang Y; Hong Z
    Front Genet; 2023; 14():1198834. PubMed ID: 37396034
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
    Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Ferreira Cristina S; Polo B; Lacerda JF
    Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.
    De Roeck L; Michaux L; Debackere K; Lierman E; Vandenberghe P; Devos T
    Hematology; 2018 Dec; 23(10):785-792. PubMed ID: 29993347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis- and Prognosis-Related Gene Alterations in
    Morishita S; Komatsu N
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629188
    [No Abstract]   [Full Text] [Related]  

  • 12. Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.
    Skov V
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the
    Pennisi MS; Di Gregorio S; Tirrò E; Romano C; Duminuco A; Garibaldi B; Giuffrida G; Manzella L; Vigneri P; Palumbo GA
    Hematol Rep; 2023 May; 15(2):317-324. PubMed ID: 37367082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
    Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
    Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
    Verma T; Papadantonakis N; Peker Barclift D; Zhang L
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
    Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
    Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience.
    Alduaij W; McNamara CJ; Schuh A; Arruda A; Sukhai M; Kanwar N; Thomas M; Spiegel J; Kennedy JA; Stockley T; Tsui H; Devlin R; Sibai H; Maze D; Schimmer A; Yee K; Chan S; Kamel-Reid S; Gupta V
    Hemasphere; 2018 Jun; 2(3):e44. PubMed ID: 31723772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
    Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
    Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.